Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial
Advanced Science · 2025
DOI: 10.1002/advs.202509668 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, 2025. Verfasst von Shanika Samarasekera und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, B15 2TH, United Kingdom. Hauptthemen laut MEDLINE: Immunomodulation, Status Epilepticus, Anticonvulsants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Refractory Status Epilepticus (RSE) is a neurological emergency associated with considerable morbidity and mortality. The molecular mechanisms contributing to neuroinflammation in RSE are increasingly being recognized. Despite its severity, high‐quality and conclusive evidence is lacking for many RSE treatments, especially regarding the optimization of antiseizure medications and emerging immunotherapies. In this manuscript, the use of immunotherapy as a valuable treatment option in RSE is reviewed. The example of Toclizumab is used, its potential efficacy demonstrated by a case series from our center. Traditional clinical trial designs have proven inadequate in efficiently addressing these evidence gaps for this complex and heterogeneous condition. In examining the wider evidence for the use of anti‐inflammatory agents, including early immunotherapy, the scope for adaptive platform trials is explored to be utilized to develop an evidence base in this area. Neuroinflammation plays a role in propagating seizures and associated neuronal injury in RSE; these pathways may be amenable to immunomodulation. In this review, the limitations of existing observational data and the need for efficient, quickly translatable clinical trials are highlighted to evaluate multiple interventions for RSE. Innovative trial designs, such as adaptive platform trials, help generate robust evidence for rapid uptake in RSE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, B15 2TH, United Kingdom.
- Department of Anesthesia, Critical Care and Acute Care Medicine, The Royal Wolverhampton NHS Trust, Wolverhampton, West Midlands, WV10 0QP, United Kingdom.
- Neuroscience and Ophthalmology, Department of Inflammation and Ageing, School of Infection, University of Birmingham, Birmingham, West Midlands, B15 2TH, United Kingdom.
- Department of Neurosciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, B15 2TH, United Kingdom.
- Department of Neurology, The Royal Wolverhampton NHS Trust, New Cross Hospital, Wolverhampton, UK, WV1 1LY, United Kingdom.
- Department of Critical Care, University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, B15 2TH, United Kingdom.
ORCID-Profile: Cyril Chacko, Randeep Mullhi, Ruoling Chen, Suresh Renukappa, Tonny Veenith
Zitieren
APA
Samarasekera, S., Thilak, S., Patel, A., Nasa, P., Ahmed, Z., Jacques, L., Scotton, W. J., Chacko, C., Mullhi, R., Chen, R., Patil, V., Renukappa, S., & Veenith, T. (2025). Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial. Advanced Science. https://doi.org/10.1002/advs.202509668
Vancouver
Samarasekera S, Thilak S, Patel A, Nasa P, Ahmed Z, Jacques L, et al. Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial. Advanced Science. 2025. doi:10.1002/advs.202509668
BibTeX
@article{Samarasekera2025,
author = {Samarasekera, Shanika and Thilak, Suneesh and Patel, Asha and Nasa, Prashant and Ahmed, Zubair and Jacques, Lorraine and Scotton, William J and Chacko, Cyril and Mullhi, Randeep and Chen, Ruoling and Patil, Vikram and Renukappa, Suresh and Veenith, Tonny},
title = {Refractory Status Epilepticus and Therapeutic Uncertainties: a Comprehensive Review on Targeting Neuroinflammation and Rationale for Developing a Platform Trial},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202509668}
}
EUVIMED